FDA 483 - Winder Laboratories, LLC - August 05, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Winder Laboratories, LLC received a Form 483 with numerous significant observations related to its drug manufacturing operations. Key issues include quality control unit failures, premature product release, inadequate stability testing, lack of process validation, and widespread deficiencies in cleaning, equipment maintenance, and documentation practices. These findings indicate a systemic lack of adherence to cGMP regulations, posing potential risks to drug product quality, safety, and efficacy.
ID · fc784622-93a0-49c4-ae0c-d3ac8a9882cd